← Back to search

Beam Therapeutics Inc

BEAM · NASDAQ

Biological Product (except Diagnostic) Manufacturing

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

ESG Scores

Overall ESG
4.6
Environmental
6.6
Social
3.6
Governance
5.5

Gender Diversity

Female Directors0.4286%
Female Executives0.18972332015810275%
CEO GenderMale